[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephropathy-diabetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephropathy-diabetic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100650535","del-1-and-thromboxane-a2-in-diabetic-nephropathy-patients-100650535",false,"NCT07749664","DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients","Developmental Endothelial Locus-1 Serum Level and Its Relation With Thromboxane A2 and Platelet Count in Patients With Diabetic Nephropathy","DEL1-DN","Inclusion Criteria:\n\n* Adult patients aged between 18 and 70 years.\n* Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings.\n* Patients undergoing evaluation or follow-up for diabetic kidney disease.\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* \\- Patients with known hepatic disease.\n* Patients with significant cardiovascular disease.\n* Patients with malignancy.\n* Patients who have undergone recent surgery.\n* Patients with known hematological disorders or hypercoagulable states.\n* Patients receiving medications that significantly affect platelet function.","ALL","18 Years","70 Years",{"count":21,"type":22},80,"ESTIMATED","1 Year","OBSERVATIONAL","Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression.\n\nDevelopmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction.\n\nThis study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity.\n\nThis observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.",[27],"Nephropathy, Diabetic","NOT_YET_RECRUITING","2026-08-02",{"date":31,"type":32},"2026-08-06","ACTUAL",{"date":34,"type":22},"2026-09-01",{"date":36,"type":22},"2027-01-01",{"name":38,"class":39},"Aswan University","OTHER"]